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ABSTRACT 
Background: Taxol (paclitaxel) inhibits proliferation and induces apoptosis in a variety of cancer cells, but it also 
upregulates cytoprotective proteins and/or pathways that compromise its therapeutic efficacy. Materials and Method: 
The roles of GM3 synthase (α2,3-sialyltransferase, ST3Gal V) in attenuating Taxol-induced apoptosis and triggering 
drug resistance were determined by cloning and overexpressing this enzyme in the SKOV3 human ovarian cancer cell 
line, treating SKOV3 and the transfectants (SKOV3/GS) with Taxol and determining apoptosis, cell survival, clono-
genic ability, and caspase-3 activation. Results: In this report, we demonstrated that Taxol treatment resulted in apop-
tosis which was associated with caspase-3 activation. Taxol treatment upregulated the expression of human GM3 syn-
thase, an enzyme that transfers a sialic acid to lactosylceramide. Moreover, we cloned the full-length GM3 synthase 
gene and showed for the first time that forced expression of GM3 synthase attenuated Taxol-induced apoptosis and in-
creased resistance to Taxol in SKOV3 cells. Conclusions: GM3 synthase overexpression inhibited Taxol-triggered 
caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of 
Taxol therapy. 
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1. Introduction 
Epithelial ovarian cancer is the major cause of death in 
women with gynecological malignancies [1]. Taxol is 
one of the most active cancer chemotherapeutic agents 
known and is effective against several human malignan- 
cies, including ovarian cancer [2,3]. Taxol promotes mi- 
crotubule (MT) assembly, which produces a change in 
MT dynamics that disrupts the reorganization of the 
microtubule network required for mitosis and cell prolif- 
eration [4]. As a result, cells treated with Taxol are ar- 
rested in the G1 and G2/M phases of the cell cycle [5]. 
Taxol triggers apoptosis in ovarian cancer cells, but also 
upregulates cytoprotective proteins and/or pathways that 
compromise its therapeutic efficacy [6,7]. Moreover, 
defects in apoptotic signals contribute to drug resistance 
in ovarian cancer [8]. Strategies to lower the threshold 
for triggering cancer cell apoptosis may lead to new and 
more effective therapeutic regimens for ovarian cancer. 
Therefore, targeted therapeutics against the Taxol-in- 
duced cytoprotective signals may offer a rational strategy 
to improve the anticancer efficacy of Taxol. 
Sialyltransferases (ST) play a role in a variety of 
biological processes, including cell-cell communication, 
cell-matrix interaction, adhesion, and protein targeting 
[9-11]. Six human α2,3-sialyltransferase genes, hST3Gal 
I-VI, have been cloned. These multiple genes encode 
enzymes with closely related catalytic specificities but 
different patterns of tissue expression [12]. It was re- 
ported that the mRNA and activity levels of a member of 
the ST family, α2,3-sialyltransferase ST3Gal V (GM3 
synthase) [13], positively correlated with resistance to 
the synthetic retinoid N-(4-hydroxyphenyl)-retinamide 
[14] in A2780 human ovarian carcinoma cells. Moreover, 
Noguchi et al. [15] established GM3 synthase over- 
expressing cells by transfecting the cDNA of GM3 
synthase into a GM3-deficient subclone of the 3LL 
Lewis lung carcinoma cell line and demonstrated that 
these cells were resistant to apoptosis induced by eto- 
poside and doxorubicin by upregulating Bcl-2 expression 
in these cells. The acquisition of anticancer drug resis- 
tance by transfecting the GM3 synthase cDNA into these 
cells was associated with selective attenuation of both  *Corresponding author. 
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caspase-9 and caspase-3, indicating that the antiapoptosis 
signaling effect of GM3 synthase could be involved 
upstream of caspase-9 [15]. Recent data revealed that 
elevated mRNA levels of GM3 synthase positively 
correlate with a high risk of pediatric acute leukemia [16]. 
Moreover, GM3 synthase silencing suppressed lung 
metastasis in murine breast cancer cells [17]. Interestingly, 
the GM3 synthase gene is a biomarker for histological 
classification as well as drug sensitivity against epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors 
in non-small cell lung cancer [18]. Additionally, insulin 
resistance, a membrane microdomain disorder, depends 
on increased ganglioside GM3 biosynthesis following 
upregulated GM3 synthase gene expression [19]. 
The roles of GM3 synthase in Taxol resistance or 
apoptosis triggered by this anticancer agent have not been 
delineated. In this project, we explored whether Taxol 
treatment increased the expression of GM3 synthase in 
SKOV3 human ovarian cancer cells, and whether forced 
expression affected the sensitivity of these cells to 
apoptosis, thereby altering the efficacy of Taxol therapy. 
2. Materials and Methods 
2.1. Cell Culture and Taxol Treatment 
The human SKOV3 ovarian cell line was purchased from 
American Type Culture Collection (ATCC, Rockville, 
MD). Cells were maintained in RPMI1640 media (Medi- 
atec, Inc., Herndon, VA) supplemented with 10% fetal 
bovine serum (FBS) at 37˚C in 5% CO2. Generally, 2 × 
105 cells/well were plated in six-well plate and incubated 
overnight. The next day, 100 nM Taxol dissolved in di- 
methylsulfoxide (DMSO) were added into the indicated 
wells, and an equal amount of DMSO was added into 
control wells. The final concentration of DMSO was less 
than 0.1%. At 48 h after treatment, cells were col- lected 
for apoptosis analysis. 
2.2. Cloning the GM3 Synthase Gene 
To clone the full-length GM3 synthase gene, we used the 
GM3 synthase sense primer  
5’-GACATGGCTTCTGTTCCAAT-3’ and the GM3 syn- 
thase antisense primer 
5’-TGTTCAAAATTCACGATCAATGCC-3’ to amplify 
the coding region of the GM3 synthase gene in SKOV3 
cells by PCR. The full-length GM3 synthase DNA frag- 
ment was separated on 1.5% agarose gel and purified by 
a gel extraction kit (Qiagene #28704). The purified GM3 
synthase DNA fragment was subcloned into the pEF6/ 
V5-His TOPO expression vector (Invitrogen Corp., Carls- 
bad, CA) following the protocol provided by the com- 
pany. Four µL of gel-purified PCR product, 1 µL reac- 
tion salt buffer, and 1 µL TOPO vector were mixed gen- 
tly and incubated at room temperature for 5 min. Two µL 
of the reaction mixture were added into a vial of ONE 
SHOT top 10 chemically competent E. coli and mixed 
gently. This mixture was kept on ice for 30 min, and then 
this mixture was heat shocked at 42˚C for 30 sec. After 
heat shock, the vial was immediately transferred onto ice. 
Then, 250 µL of room temperature SOC medium were 
added to the vial. The vial was capped tightly and shaken 
horizontally at 200 rpm for one h at 37˚C. Ten to 50 µL 
of transformed E. coli were spread onto an ampicillin 
selective plate. The obtained GM3 synthase clones were 
further confirmed by DNA sequence analysis. 
2.3. Establishing a Stable SKOV3 Cell Line with 
Exogenous GM3 Synthase Gene 
SKOV3 cells were grown in a 6-well plate (2 × 105 
cells/well) overnight. The human ovarian SKOV3 cells 
were transfected with the GM3/V5-His plasmid or empty 
pEF/V5-His plasmid by using lipofectamine 2000 trans- 
fection reagent according to the manufacturer instruct- 
tions (Invitrogen). For cell transfection in each well, 5 
µL lipofectamine 2000 were added into 250 µL Opti- 
MEM serum reduced medium, and 4 µg plasmid DNA 
were added into another 250 µL Opti-MEM serum re- 
duced medium. Each mixture was vortexed briefly and 
kept at room temperature for 5 min, then the mixtures 
were combined and kept at room temperature for 20 min. 
Five hundred µL of the mixture were then added evenly 
into a well of a 6-well plate; the plate was then shaken 
gently to thoroughly mix the transfection reagent and 
plasmid mix. Stable clones were obtained through 
screening transfected cells by adding 10 µg/mL Bla- 
stacidin (Invitrogen) to the growth medium at 24 h after 
transfection. After 2 - 4 weeks of growth, over-expres- 
sion of GM3 synthase in the transfectants was confirmed 
by Western blot analysis using V5 antibody. The con- 
firmed transfectants were expanded and stored for future 
studies. 
2.4. RNA Isolation and RT-PCR 
Total RNA was isolated using the RNeasy Mini Kit 
(Qiagen, Valencia, CA) as described by the manufacturer. 
Two µg of total RNA were used in reverse transcription 
reactions with M-MLV reverse transcriptase and oligo 
(dT) 15 primer (Promega, Madison, WI) as described by 
the manufacturer. One µL oligo-dT 15 primer, 1 µL 
dNTP, and 2 µg total RNA were mixed and the total re- 
action volume was brought to 18 µL by adding nucle- 
ase-free water. The reaction mixture was kept at 70˚C for 
10 min, and then the mixture was immediately trans- 
ferred onto ice. Then, 5 µL 5× reaction buffer, 1 µL 
M-MLV reverse transcriptase, and 0.5 µL nuclease in- 
hibitor were added into the mixture, and the total 25 µL 
reaction volume was reached by adding nuclease-free 
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water. This reaction mixture was kept at 42˚C for 1 h for 
cDNA synthesis, followed by 70˚C for 15 min to deacti- 
vate M-MLV reverse transcriptase. Four µL of the re-
sulting total cDNA were then used as the template in 
PCR to measure the mRNA level of interest using the 
designed primers for GM3 synthase: sense,  
5’-AAAGGAAACCCTGCCATTCT-3’; antisense,  
5’-TCACCACTCCCTCTTTGACC-3’. β-actin mRNA 
levels were used as internal controls. The sense primer 
for actin amplification is  
5’-GCCCCCCTGAACCCCAAGGCCAAC-3’. The anti- 
sense primer for actin amplification is  
5’-CCGGTCGGCCGTGGTGGTGAAGCT-3’. Four µL 
total cDNA, 1 µL (5 pmol) primer, and 12.5 µL Gotaq 
Green Master Mix (Promega #M7122) were mixed and a 
total 25 µL reaction volume was reached by adding 6.5 
µL nuclease-free water. The reactions were performed 
with denaturation at 95˚C for 55 sec, annealing at 55˚C 
for 55 sec, and extension at 72˚C for 2 min for a total of 
30 cycles. The amplified fragments were separated on 
1.5% agarose gel and visualized under ultraviolet light by 
ethidium bromide staining. 
2.5. Cell Survival Assay 
The cell survival assay was performed as we previously 
described [20]. Cells were treated with 10 - 500 nM of 
Taxol for 48 h. After harvesting the cells, survival was 
determined by cell survival assay. For each treatment, 1 
× 104 cells were seeded into a 96-well plate and treated 
with or without CMH. Cells were stained with 1% me- 
thylene blue in 50% methanol. After the plates were 
washed with PBS, the dye was dissolved in 100 μL of 0.5 
M HCl. Absorbance was determined by an automated 
scanning photometer at a wavelength of 630 nM. 
2.6. Annexin V Ainding Assay for Detecting 
Early Apoptotic Cells 
Following treatment as stated above, the cells (5 × 105 
cells/treatment) were used to determine the translocation 
of phosphatidylserine to the outer surface of the plasma 
membrane during apoptosis using the annexin V binding 
assay. For this assay, the cells were incubated with Taxol 
as described above, harvested, and stained with fluo- 
rescein isothiocyanate-labeled annexin V (BD Biosci- 
ences, San Jose, CA) and propidium iodide according to 
the manufacturer protocol. All harvested cells were 
washed two times with PBS then suspended in 300 µL 
annexin V binding buffer. For each sample, 100 µL cell 
suspension, 5 µL annexin V FITC-conjugated antibody 
and 1 µL 250 µM propidium iodide were mixed and kept 
in darkness place at room temperature for 30 min. Then, 
another 400 µL of annexin V binding buffer were added 
into each sample for final flow cytometry analysis. 
Apoptosis and necrosis were analyzed by quadrant statis- 
tics on the propidium iodide (PI)-negative, fluorescein- 
positive cells, and PI-positive cells, respectively. 
2.7. Detection of Apoptosis by DAPI Staining 
DAPI staining was performed on untreated and Taxol- 
treated cells as described previously [20]. Briefly, prior 
to staining, the cells were fixed with 4% paraformalde- 
hyde for 30 min at room temperature. After washing with 
PBS by centrifugation at 650 × g, DAPI was added to the 
fixed cells for 5 min, then the cells were examined by 
fluorescence microscopy. Apoptotic cells were identi- 
fied by condensation and fragmentation of nuclei. A 
minimum of 300 cells were counted for each treatment, 
and the percentage of apoptotic cells was calculated as 
the ratio of apoptotic cells to total cells counted ×100. 
2.8. Clonogenic Assay 
Clonogenic assay was carried out as we previously de- 
scribed [21]. SKOV3 cells were transfected with EF6 or 
GM3Syn-EF6 expression vector, treated with or without 
5 or 10 nM Taxol for 48 h, and after washing the cells 
with growth media lacking Taxol, they were grown for 7 
days. The colonies in control or Taxol-treated wells were 
then counted. Error bars represent the standard deviation 
for each point obtained from triplicate experiments. 
2.9. Western Blot Analysis 
In this study, the following primary antibodies were used: 
anti-caspase-3 (Cell Signaling Technology, Danvers, 
MA), anti-V5 antibody (Invitrogen Corp., Carlsbad, CA), 
anti-β-actin clone AC-74 (Sigma-Aldrich, St. Louis, MO). 
Protein concentrations were determined by using the 
BCA/Cu2SO4 protein assay (Sigma-Aldrich) as described 
by the manufacturer. For Western blot analysis, 50 - 80 
µg protein/lane were separated by 12% SDS-PAGE, 
blotted onto a PVDF Immobilon membrane, and then 
protein levels were detected using peroxidase-conjugated 
secondary antibodies as described by the manufacturer. 
The primary antibody was used at a concentration of 
1:2000 (v/v). The membranes were then exposed to Ko- 
dak X-Omat film for various times. The mouse mono- 
clonal anti-β-actin (clone AC-74) was purchased from 
Sigma-Aldrich and used at 1:5000 (v/v). 
3. Results 
3.1. GM3 Synthase Is Induced during 
Taxol-Induced Apoptosis 
We have found that Taxol at 100 - 500 nM induces ro- 
bust apoptosis in cell lines from different types of cancer 
[22]. As shown in Figure 1(a), the annexin V binding 
assay revealed that Taxol at 100 nM induced early apop-  
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Figure 1. Taxol-induced apoptosis and GM3 synthase ex-
pression in SKOV3 cells. (a) Cells were treated with 100 nM 
Taxol for 48 h, harvested, and apoptosis was determined by 
FACS analysis as described in Materials and Methods. 
Compensation was executed for each experiment using un-
treated cells and cells stained only with annexin V or 
propidium iodide, respectively. Error bars show standard 
deviation from triplicate measurements (*P < 0.05); (b) Total 
RNA from SKOV3 cells was extracted and the levels of GM3 
synthase mRNA were measured by RT-PCR. β-actin was 
used as an internal control in the RT-PCR reactions; (c) 
SKOV3 and SKOV3/GS cells were treated with 100 nM of 
Taxol for 48 h and apoptotic cell death was determined by 
DAPI staining as described in Materials and Methods (c1 
and c3 are control untreated SKOV3 and SKOV3/GS, re-
spectively; c2 and c4 SKOV3 and SKOV3/GS cells treated 
with 100 nM Taxol, respectively); (d) Apoptotic cells were 
identified by condensation and fragmentation of nuclei. A 
minimum of 300 cells were counted for each treatment, and 
the percentage of apoptotic cells was calculated. Error bars 
show S.D. from triplicate measurements. 
tosis in 28% of SKOV3 cells, and RT-PCR analysis 
showed that while SKOV3 cells express little GM3 syn- 
thase at the mRNA level, it was significantly increased 
after Taxol treatment (Figure 1(b)). These data suggest 
that Taxol induces GM3 synthase expression. 
3.2. Expression of GM3 Synthase Decreases 
Taxol-Induced Apoptosis in SKOV3 Cells 
To determine the role of GM3 synthase in Taxol-induced 
apoptosis, we constructed a GM3 synthase III-EF6 plas- 
mid and transfected SKOV3 cells. Stable SKOV3 trans- 
fected populations harboring this plasmid contained ele- 
vated levels of GM3 synthase as determined by im- 
munoblot analysis (Figure 2). As revealed by annexin V 
binding assay, treating SKOV3 cells with 100 nM Taxol 
for 48 h induced early apoptosis in 28% - 30% of the 
cells, as compared to 17% in transfectants overexpress- 
ing GM3 synthase (SKOV3/GS) (Figures 1(a) and (b)). 
These results show that the overexpression of GM3 syn- 
thase reduces early apoptosis triggered by Taxol in 
SKOV3/GS cells (P < 0.05). Next, we determined the 
levels of late apoptosis induced by Taxol in SKOV3 and 
SKOV3/GS cells by DAPI staining. Apoptotic cells were 
identified by condensation and fragmentation of nuclei. 
The data shown in Figures 1(c) and (d) clearly show that 
Taxol induced apoptosis as visualized by DAPI staining 
of these cells treated with 10 - 100 nM Taxol. Quantita- 
tion of apoptosis assessed by DAPI staining revealed that 
treating the cells with 10 - 100 μM Taxol for 48 h in- 
duced 60% - 80% apoptosis in SKOV3 cells, but only  
 
 
Figure 2. GM3 synthase prevents caspase-3 activation. 
Western blot analysis of GM3 synthase expression in 
SKOV3/GS cells using V5 antibody. SKOV3 and SKOV3/ 
GS cells were treated with 100 nM Taxol for 48 h and GM3 
synthase was detected by Western blot analysis using V5 
antibody as described in the Material and Methods. Note 
that forced expression of GM3 synthase attenuates 
Taxol-induced apoptosis (Figure 1(a)) and caspase-3 activa-
tion. 
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triggered 35% - 38% apoptosis in SKOV3/GS cells, in- 
dicating that GM3 synthase overexpression attenuates 
late Taxol-induced apoptosis. 
To determine whether overexpression of GM3 syn- 
thase in SKOV3 transfectants increases cell proliferation, 
we determined number of cells after 48 h of culturing as 
described in Materials and Methods. As shown in Figure 
3(a), GM3 synthase-overexpressing cells displayed 20%  
 
 
              (a)                          (b) 
 
(c) 
Figure 3. GM3 synthase increases proliferation and de- 
creases Taxol cytotoxicity in SKOV3/GS cells. (a) SKOV3 
and SKOV3/GS cells were grown for 48 h and the number 
of cells was determined as described in Materials and 
Methods; (b) SKOV3 and SKOV3/GS cells were treated 
with 1 - 100 nM Taxol for 48 h and the numbers of cells 
which survived was determined by methylene blue cytotox- 
icity assay as described in Materials and Methods; (c) 
SKOV3 cells untreated and SKOV3 cells treated with 5 or 
10 nM Taxol for 48 h; SKOV3/GS untreated cells and 
SKOV3/GS cells treated with 5 or 10 nM Taxol for 48 h as 
described in the Materials and Methods. Colonies were 
counted 7 days later. The values are representative of trip- 
licate counts and error bars show standard deviations. 
increased proliferation compared to SKOV3 cells. More- 
over, to determine whether Taxol decreases cell survival 
to the same extent in SKOV3 and GM3 synthase-over- 
expressing SKOV3/GS cells, we treated these cells with 
increasing concentrations of Taxol and determined cell 
survival by methylene blue cell survival assay as de- 
scribed in Materials and Methods. The results shown in 
Figure 3(b) revealed that SKOV3/GS survived cells are 
about 2 - 3-fold more resistant to Taxol than SKOV3 
cells. 
To examine whether GM3 synthase-overexpressing 
cells exhibited resistance to Taxol, we executed a colony 
forming assay. Clonogenic assay was carried out as de- 
scribed in Materials and Methods. As shown in Figure 
3(c), more colonies were survived in SKOV3/GS cells 
compared to SKOV3 cells following treatment with 5 
and 10 nM Taxol. 
We also examined the role of caspase-3 in Taxol-in- 
duced apoptosis in SKOV3 and SKOV3/GS cells, since it 
is a central caspase in the mitochondrial apoptotic sig- 
naling pathway. SKOV3 cells were treated with Taxol 
and caspsase-3 levels were analyzed by immunoblotting. 
As shown in Figure 2(a), Taxol induced the processing 
of caspase-3 to its active forms, revealing that caspase-3 
is involved in mediating Taxol death signals. While the 
results shown in Figure 2 demonstrated that Taxol in- 
duced processing of procaspase-3 to its active forms, the 
ectopic expression of GM3 synthase inhibited this proc- 
ess, and barely active caspase-3 forms were detected ex- 
pressing GM3 synthase. These data clearly show that 
GM3 synthase functions as an endogenous caspase-3 
inhibitor in SKOV3 cells. 
4. Discussion 
Our previous results showed that Taxol-induced apop- 
tosis in SKOV3 ovarian cancer cells is associated with 
caspase-8, -9, and -3 activation in these cells [22]. De- 
spite cytoreductive surgery and primary chemotherapy, 
advanced epithelial ovarian cancer is a highly lethal ma- 
lignancy [23]. Usually, following an initial high response 
rate, the patient relapses and the tumor acquires resis- 
tance to chemotherapy. Defects in apoptotic signaling 
pathways contribute to drug resistance in ovarian cancer 
[24,25]. In the search to identify novel cytoprotective 
signaling molecules which attenuate Taxol-triggered 
apoptosis, we found for the first time that GM3 synthase 
expression was upregulated in Taxol-treated SKOV3 
cells. Furthermore, we found that increased expression of 
GM3 synthase served a cytoprotective function, pre- 
vented early and late Taxol-induced apoptosis, and was 
associated with caspase-3 activation. 
GM3 synthase is a member of the sialyltransferase 
family which catalyzes ganglioside GM3 biosynthesis.  
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Gu et al. [17] demonstrated that GM3 synthase silencing 
suppressed lung metastasis in murine breast cancer cells. 
Conversely, compared to wild-type cells, stable overex- 
pression of sialyltransferase-1 (SAT-1, GM3 synthase) or 
pharmacological manipulation of A2780 human ovarian 
cancer cells with N-(4-hydroxyphenyl) retinamide had 
elevated ganglioside levels, reduced in vitro cell motility, 
and enhanced expression of the membrane adaptor pro- 
tein caveolin-1 [26]. In GM3 synthase-overexpressing 
clones, both depletion of gangliosides by treatment with 
the glucosylceramide synthase inhibitor D-threo-1-phenyl- 
2-decanoylamino-3-morpholino-1-propanol and silencing 
of caveolin-1 by siRNA increased in vitro cell motility 
[27]. 
To our knowledge, this is the first report describing the 
role of GM3 synthase in attenuating Taxol-induced cell 
death and causing resistance to this agent in SKOV3 cells. 
Previous work has shown that transfection with GM3 
synthase in a GM3-deficient clone derived from a murine 
Lewis lung carcinoma cell line increased colony forma- 
tion and resistance to apoptosis [15]. Moreover, GM3 
synthase-deficient lymphoid cells underwent Fas-induced 
apoptosis [28]. Interestingly, recent results by Ohkawa et 
al. [29] also showed that Wisp2/CCN5, a member of the 
CCN family proteins involved in cell proliferation, an- 
giogenesis, tumorigenesis, and wound healing, was upre- 
gulated in nervous tissues in GM3-only mice. Further- 
more, Wisp2/CCN5-overexpressing cells were resistant 
to apoptosis induced by H2O2. Our study suggests that 
GM3 synthase as an anti-apoptotic protein may be of 
value as a therapeutic target in various cancers, and could 
also serve as a diagnostic marker for identifying drug- 
resistant tumors. 
Identifying the critical apoptosis regulatory molecular 
targets of Taxol in cancer cells may lead to improved 
cancer therapy regimens that utilize a lower dose of 
Taxol, thereby limiting systemic toxicities. Moreover, 
identifying novel cytoprotective molecules such as GM3 
synthase capable of preventing Taxol-triggered apoptosis 
validates these molecules as rational targets to sensitize 
cancers to Taxol death signals. Investigating these targets 
and their roles in Taxol-induced apoptosis will also pro- 
vide novel information on the specific signaling path- 
ways involved in this process, which could be useful for 
discovering drugs with greater selectivity and efficacy. 
The molecular mechanism of upregulating GM3 syn- 
thase by Taxol and how it decreases caspase-3 activation 
are of great interest. Furthermore, strategies to reduce the 
expression of GM3 synthase and/or inhibit its activity by 
small molecule inhibitors are likely to render cancer cells 
more sensitive to Taxol-induced apoptosis. 
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